Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells
Giuseppa Augello(Institute for Biomedical Research and Innovation), Melchiorre Cervello(Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy)
Cited by 47
Related Papers
NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance
|Cell Death and Disease|2016|141
Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation
|International Journal of Oncology|2017|94
Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells
|PLoS ONE|2013|50
New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells
|Pharmaceutics|2023|27